Akanocure

Executive Summary

Akanocure is a private, US-based biotechnology company founded in 2018 and headquartered in San Diego, with an additional address in West Lafayette, Indiana. The company specializes in developing novel small molecule therapeutics for oncology, with a primary focus on orphan diseases and unmet medical needs, particularly in blocking cancer metastasis. Leveraging a proprietary chemistry platform integrated with drug discovery expertise, Akanocure aims to address critical gaps in cancer treatment by targeting metastatic processes. Despite its innovative approach, the company remains in early stages with no disclosed pipeline, funding history, or valuation, limiting visibility into its development progress. However, its targeted niche in anti-metastatic therapies, combined with a robust platform, positions it as a potential player in the oncology space, subject to successful advancement of its preclinical programs.

Upcoming Catalysts (preview)

• TBDDisclosure of lead candidate and preclinical data40% success
• TBDSeries A or seed funding round announcement50% success
• TBDPartnership or licensing deal with academic or industry partner30% success